{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T04:44:52Z","timestamp":1693370692931},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The study was sponsored by AbbVie. AbbVie contributed to the study design, research, and interpretation of data, and the writing, reviewing, and approving of the publication."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00280-017-3262-4","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T10:21:03Z","timestamp":1488277263000},"page":"587-594","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer"],"prefix":"10.1007","volume":"79","author":[{"given":"Rajendar K.","family":"Mittapalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silpa","family":"Nuthalapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie Peacock","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"3262_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrd1718","volume":"4","author":"P Jagtap","year":"2005","unstructured":"Jagtap P, Szab\u00f3 C (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421\u2013440. doi: 10.1038\/nrd1718","journal-title":"Nat Rev Drug Discov"},{"key":"3262_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3399","volume":"12","author":"NJ Curtin","year":"2012","unstructured":"Curtin NJ (2012) DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12:801\u2013817. doi: 10.1038\/nrc3399","journal-title":"Nat Rev Cancer"},{"key":"3262_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc2342","volume":"8","author":"T Helleday","year":"2008","unstructured":"Helleday T, Petermann E, Lundin C et al (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8:193\u2013204. doi: 10.1038\/nrc2342","journal-title":"Nat Rev Cancer"},{"key":"3262_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5:387\u2013393. doi: 10.1016\/j.molonc.2011.07.001","journal-title":"Mol Oncol"},{"key":"3262_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245\u2013251. doi: 10.1016\/S0140-6736(10)60893-8","journal-title":"Lancet"},{"key":"3262_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet Lond Engl 376:235\u2013244. doi: 10.1016\/S0140-6736(10)60892-6","journal-title":"Lancet Lond Engl"},{"key":"3262_CR7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0887","author":"G Kim","year":"2015","unstructured":"Kim G, Ison G, McKee AE et al (2015) FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. doi: 10.1158\/1078-0432.CCR-15-0887","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3262_CR8","doi-asserted-by":"publisher","unstructured":"(2017) Rucaparib Approved for Ovarian Cancer. Cancer Discov. 7:120-121.\u00a0doi: 10.1158\/2159-8290.CD-NB2016-164","DOI":"10.1158\/2159-8290.CD-NB2016-164"},{"key":"3262_CR9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1158\/1078-0432.CCR-1144-3","volume":"10","author":"NJ Curtin","year":"2004","unstructured":"Curtin NJ, Wang L-Z, Yiakouvaki A et al (2004) Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res Off J Am Assoc Cancer Res 10:881\u2013889","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3262_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fonc.2013.00257","volume":"3","author":"JK Horton","year":"2013","unstructured":"Horton JK, Wilson SH (2013) Strategic combination of DNA-damaging agent and PARP inhibitor results in enhanced cytotoxicity. Front Oncol 3:257. doi: 10.3389\/fonc.2013.00257","journal-title":"Front Oncol"},{"key":"3262_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ctrv.2010.03.003","volume":"36","author":"C Powell","year":"2010","unstructured":"Powell C, Mikropoulos C, Kaye SB et al (2010) Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 36:566\u2013575. doi: 10.1016\/j.ctrv.2010.03.003","journal-title":"Cancer Treat Rev"},{"issue":"suppl 4","key":"3262_CR12","doi-asserted-by":"publisher","first-page":"iv150","DOI":"10.1093\/annonc\/mdu331.12","volume":"25","author":"MJA Jonge de","year":"2014","unstructured":"de Jonge MJA, van Herpen C, Gietema JA et al (2014) A study of ABT-767 in advanced solid tumors with BRCA 1 and BRCA 2 mutations and high grade serous ovarian, fallopian tube, or primary peritoneal cancer. Ann Oncol 25(suppl 4):iv150. doi: 10.1093\/annonc\/mdu331.12","journal-title":"Ann Oncol"},{"key":"3262_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.seminoncol.2016.08.005","volume":"43","author":"MS Daniels","year":"2016","unstructured":"Daniels MS, Lu KH (2016) Genetic predisposition in gynecologic cancers. Semin Oncol 43:543\u2013547. doi: 10.1053\/j.seminoncol.2016.08.005","journal-title":"Semin Oncol"},{"key":"3262_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S et al (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051\u20131065. doi: 10.2165\/00003088-200544100-00004","journal-title":"Clin Pharmacokinet"},{"key":"3262_CR15","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1200\/jco.2005.23.16_suppl.2032","volume":"23.90160","author":"J Lu","year":"2005","unstructured":"Lu J, Eppler SM, Lum BL, Halmilton M, Rakhit A, Gaudreault J (2005) A population pharmacokinetic (PK) model for erlotinib (E), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). J Clin Oncol 23.90160:2032\u20132032","journal-title":"J Clin Oncol"},{"key":"3262_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.849","author":"Y Hong","year":"2016","unstructured":"Hong Y, Passos VQ, Huang P-H, Lau YY (2016) Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase. J Clin Pharmacol. doi: 10.1002\/jcph.849","journal-title":"J Clin Pharmacol"},{"key":"3262_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2165\/00003088-199426040-00005","volume":"26","author":"DJ Morgan","year":"1994","unstructured":"Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26:292\u2013307. doi: 10.2165\/00003088-199426040-00005","journal-title":"Clin Pharmacokinet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3262-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3262-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3262-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:34:09Z","timestamp":1498376049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3262-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3262"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3262-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}